Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Ligand Pharmaceuticals Incorporated (LGND)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ligand's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
79.77 -1.59    -1.95%
31/12 - Closed. Currency in USD ( Disclaimer )
After Hours
79.77
0.00
0.00%
16:20:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 174,373
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 79.09 - 80.96
Ligand 79.77 -1.59 -1.95%

Ligand Pharmaceuticals Incorporated Company Profile

 
Get an in-depth profile of Ligand Pharmaceuticals Incorporated, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

76

Equity Type

ORD

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Contact Information

Address 555 Heritage Drive Suite 200
Jupiter, 33458
United States
Phone 858 550 7500
Fax -

Top Executives

Name Age Since Title
John Warren Kozarich 75 2003 Independent Chairman
Shalendar Bhasin - - Scientific Advisor
Nancy Ryan Gray 64 2017 Independent Director
John L. LaMattina 74 2011 Independent Director
Martine Zimmermann - 2023 Director
Todd C. Davis 63 2007 Director
Jason Haas 56 2022 Independent Director
Jason M. Aryeh 56 2006 Independent Director
Stephen Lawrence Sabba 65 2008 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LGND Comments

Write your thoughts about Ligand Pharmaceuticals Incorporated
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mr Ax
Mr Ax Sep 02, 2021 2:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$300 next week
Ray Weber
Ray Weber Jul 26, 2021 2:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Earnings today.
Thakur Rathi
Thakur Rathi Feb 22, 2021 9:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this could be another short squeeze
Adonis Whelan
Adonis Whelan Feb 18, 2021 3:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just bought
Ja Ni
Ja Ni Feb 04, 2021 5:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
let wall street bets know about this
Oscar Jimenez
Oscar Jimenez Feb 04, 2021 11:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
easy 300, high growth profitable company with lots of shorties to squeeze
János Török
János Török Feb 04, 2021 4:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
short squeeze, after the good earning result?
Le Ra
Le Ra Jan 24, 2021 3:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
short squeeze?
Joe Keuro
Joe Keuro Jun 17, 2019 2:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy now
Mark Stone
Mark Stone May 03, 2019 11:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What in the world
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email